{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T15:12:21Z","timestamp":1761837141685,"version":"build-2065373602"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"KL2 Mentored Career Development Award"},{"name":"University of Buffalo\u2019s"},{"DOI":"10.13039\/100018188","name":"Clinical and Translational Science Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018188","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UTHSC Cancer Research Fund"},{"name":"IREACH foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A prediction model for estimating risk of therapy-related myeloid neoplasms (tMNs), a late effect with a high mortality after chemotherapy and\/or radiation, is currently unavailable. Ability to predict risk at initial cancer presentation can be key for early detection and risk mitigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using SEER-Medicare linked database, 970\u00a0390 adults diagnosed with first primary cancer from 2000 to 2011 (with follow-up through 2015) were selected. The sample was divided into training (n\u2009=\u2009582\u00a0234) and validation cohorts (n\u2009=\u2009388\u00a0156). Various tMN risk factors were used for the development of tMN prediction model: the Therapy-Related Myeloid Neoplasm Risk Score (TMNRS). TMNRS was created as a simple arithmetic sum of independent predictors of tMN weighted according to the adjusted hazard ratio from the Cox proportional hazards analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In addition to the known risk factors of chemotherapy and radiation exposure, history of autoimmune disease and granulocyte-colony stimulating factor exposure emerged as consistent predictors of tMN after each of the 5 cancers in the study. Cancer survivors were categorized into distinct risk groups with variable risk of tMN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TMNRS provides a simple and convenient office-based mechanism to identify solid cancer patients at variable risks of tMN development. This risk assessment tool provides preliminary insights that may contribute to future research on the management of patients, particularly those receiving adjuvant therapies. Further investigation is required to fully evaluate its clinical utility and potential effects on patient care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jncics\/pkaf087","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T12:05:24Z","timestamp":1757678724000},"source":"Crossref","is-referenced-by-count":0,"title":["Therapy-Related-Myeloid-Neoplasm-Risk Score: a convenient score for therapy-related myeloid neoplasms risk assessment in adult cancer patients"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6657-8647","authenticated-orcid":false,"given":"Abhay","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology, Taussig Cancer Institute, Cleveland Clinic , Cleveland, OH,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-9396","authenticated-orcid":false,"given":"Megan M","family":"Herr","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5631-1164","authenticated-orcid":false,"given":"Rahul","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Anne Arundel Medical Center , Annapolis, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rusina","family":"Karia","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospitals Community Consortium , Geauga, OH,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3835-8855","authenticated-orcid":false,"given":"Theresa","family":"Hahn","sequence":"additional","affiliation":[{"name":"Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center , Buffalo, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4216-1414","authenticated-orcid":false,"given":"Swapna","family":"Thota","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Tennessee Health Science Center , Memphis, TN,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"author":"Division of Cancer Control & Population Sciences, National Cancer Institute. Office of Cancer Survivorship","key":"2025103011042095100_pkaf087-B1"},{"key":"2025103011042095100_pkaf087-B2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(19)30818-6","article-title":"Predicting acute ovarian failure in female survivors of childhood cancer: a cohort study in the Childhood Cancer Survivor Study (CCSS) and the St Jude Lifetime Cohort (SJLIFE)","volume":"21","author":"Clark","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025103011042095100_pkaf087-B3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025103011042095100_pkaf087-B4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"volume-title":"StatPearls [Internet].","year":"2018","author":"Vakiti","key":"2025103011042095100_pkaf087-B5"},{"key":"2025103011042095100_pkaf087-B6","doi-asserted-by":"crossref","first-page":"100587","DOI":"10.1016\/j.blre.2019.100587","article-title":"From clonal hematopoiesis to myeloid leukemia and what happens in between: will improved understanding lead to new therapeutic and preventive opportunities?","volume":"37","author":"Bewersdorf","year":"2019","journal-title":"Blood Rev"},{"key":"2025103011042095100_pkaf087-B7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.seminhematol.2024.01.006","article-title":"The crossroads of cancer therapies and clonal hematopoiesis","volume":"61","author":"Singh","year":"2024","journal-title":"Semin Hematol"},{"key":"2025103011042095100_pkaf087-B8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11912-023-01382-9","article-title":"Clonal hematopoiesis of indeterminate potential: current understanding and future directions","volume":"25","author":"Singh","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"2025103011042095100_pkaf087-B9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","article-title":"Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly","volume":"130","author":"Zink","year":"2017","journal-title":"Blood"},{"key":"2025103011042095100_pkaf087-B10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1053\/j.seminhematol.2016.10.002","article-title":"Clonal hematopoiesis","volume":"54","author":"Jan","year":"2017","journal-title":"Semin Hematol"},{"key":"2025103011042095100_pkaf087-B11","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"2025103011042095100_pkaf087-B12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"2025103011042095100_pkaf087-B13","first-page":"1606","article-title":"Clonal hematopoiesis and nonhematologic disorders","volume":"136","author":"Jaiswal","year":"2020","journal-title":"Blood"},{"key":"2025103011042095100_pkaf087-B14","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.leukres.2013.04.007","article-title":"Myelodysplastic syndromes and autoimmune diseases\u2014case series and review of literature","volume":"37","author":"Al Ustwani","year":"2013","journal-title":"Leuk Res"},{"key":"2025103011042095100_pkaf087-B15","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/S2352-3026(22)00138-7","article-title":"Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?","volume":"9","author":"Hochman","year":"2022","journal-title":"Lancet Haematol"},{"key":"2025103011042095100_pkaf087-B16","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1200\/JCO.2009.25.8723","article-title":"Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review","volume":"28","author":"Lyman","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025103011042095100_pkaf087-B17","doi-asserted-by":"crossref","first-page":"945","DOI":"10.6004\/jnccn.2011.0077","article-title":"Long-term outcomes of myeloid growth factor treatment","volume":"9","author":"Lyman","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"2025103011042095100_pkaf087-B18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1365-2141.1998.01014.x","article-title":"Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults","volume":"103","author":"Kaito","year":"1998","journal-title":"Br J Haematol"},{"key":"2025103011042095100_pkaf087-B19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2025103011042095100_pkaf087-B20","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s11764-023-01414-0","article-title":"Survivorship science at the National Institutes of Health 2017-2021","volume":"18","author":"Mollica","year":"2024","journal-title":"J Cancer Surviv"},{"key":"2025103011042095100_pkaf087-B21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"2025103011042095100_pkaf087-B22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.2021.280437","article-title":"Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer","volume":"108","author":"Petrone","year":"2023","journal-title":"Haematologica"},{"key":"2025103011042095100_pkaf087-B23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/j.seminhematol.2024.01.011","article-title":"Clonal hematopoiesis in the setting of hematopoietic cell transplantation","volume":"61","author":"Gibson","year":"2024","journal-title":"Semin Hematol"},{"key":"2025103011042095100_pkaf087-B24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminhematol.2024.01.012","article-title":"Clonal hematopoiesis and autoimmunity","volume":"61","author":"Kishtagari","year":"2024","journal-title":"Semin Hematol"},{"key":"2025103011042095100_pkaf087-B25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.seminhematol.2024.01.002","article-title":"Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence","volume":"61","author":"Pagliuca","year":"2024","journal-title":"Semin Hematol"},{"key":"2025103011042095100_pkaf087-B26","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood-2023-187424","article-title":"Can emergency hematopoiesis due to sepsis lead to clonal hematopoiesis? Implications for understanding the pathogenesis of clonal evolution","volume":"142","author":"Ogbue","year":"2023","journal-title":"Blood"},{"key":"2025103011042095100_pkaf087-B27","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1200\/JCO.2023.41.16_suppl.7010","article-title":"Identification and management of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in cancer survivors: The Cleveland Clinic experience","volume":"41","author":"Kuzmanovic","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025103011042095100_pkaf087-B28","doi-asserted-by":"crossref","first-page":"EVIDoa2200310","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"key":"2025103011042095100_pkaf087-B29","doi-asserted-by":"crossref","first-page":"e2100309","DOI":"10.1200\/PO.21.00309","article-title":"Mutant PPM1D- and TP53-driven hematopoiesis populates the hematopoietic compartment in response to peptide receptor radionuclide therapy","volume":"6","author":"Singh","year":"2022","journal-title":"J Clin Oncol Precision Oncol"},{"key":"2025103011042095100_pkaf087-B30","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap Consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2025103011042095100_pkaf087-B31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkaf087\/64285636\/pkaf087.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/9\/5\/pkaf087\/64285636\/pkaf087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/9\/5\/pkaf087\/64285636\/pkaf087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T15:04:32Z","timestamp":1761836672000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkaf087\/8255827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkaf087","relation":{},"ISSN":["2515-5091"],"issn-type":[{"type":"electronic","value":"2515-5091"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,1]]},"article-number":"pkaf087"}}